PRMT5 inhibition has recently been shown to enhance the sensitivity of breast and ovarian cancers to PARP inhibitors [72], and the convergence of alterations in DNA replication and repair genes observed in our data suggests that similar combinations could be effective against poor prognosis neuroblastoma. The gene discussed is PRMT5; the disease is ovarian carcinoma.